Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?
Optimising the roles played by both generalists and specialists in the diagnosis and treatment of Alzheimer's disease (AD) could have a major impact on the quality and cost of patient care. Therefore, one aim of the IMPACT survey was to characterise the similarities and differences between these 2 categories of physicians, in 5 different European countries, across a number of domains relevant to the medical care of people at risk for AD and those with the disease. Physician respondents comprised 250 generalists and 250 specialists from 5 European countries--France, Germany, Italy, Spain, and the United Kingdom. A substantial majority of generalists were either general practitioners or family physicians; the majority of specialists were neurologists. In April and May 2009, physician respondents completed a 30-minute, Web-based questionnaire during which they were presented with a number of multiple-choice-type questions concerning their knowledge of AD, approach to diagnosis and treatment of AD and experience of providing care for people with dementia. Generalists reported that 45% of their AD patients had mild symptoms at the initial visit compared with 60% for specialists (P < 0.001). Specialists claimed that they diagnose patients with AD themselves in 65% of cases versus 33% for generalists (P < 0.001). The main prescription treatment options employed were AD-specific medication (90%) and medication for mood or behaviour (78%). A similar percentage of generalists and specialists (77% and 75%) initiate drug treatment within 1 month of diagnosis. Overall, there were more similarities than differences between specialists and generalists regarding a broad spectrum of issues relating to AD; differences between countries appear to be greater than differences between physician groups.
Robinson
L
L
Institute for Health and Society, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK. a.l.robinson@ncl.ac.uk
Vellas
B
B
Knox
S
S
Lins
K
K
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy*; D002491:Central Nervous System Agents / Q000627:therapeutic use; D002983:Clinical Competence; D003625:Data Collection; D005060:Europe; D005194:Family Practice; D006801:Humans; D020407:Internet; D009462:Neurology; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D013038:Specialization; D011795:Surveys and Questionnaires
D002491:Central Nervous System Agents
Int J Geriatr Psychiatry. 2010 Jul;25(7):657-64
19946862
Eur J Neurol. 2007 Jan;14(1):e1-26
17222085
Dement Geriatr Cogn Disord. 2006;21(5-6):353-63
16508298
Aging Clin Exp Res. 2007 Oct;19(5):356-63
18007113
Scand J Prim Health Care. 2008;26(4):235-40
18788054
Int J Geriatr Psychiatry. 2009 Sep;24(9):895-901
19226529
J Nutr Health Aging. 2010 Aug;14(7):537-44
20818468
Gerontologist. 1999 Aug;39(4):457-64
10495584
Aging Clin Exp Res. 2007 Oct;19(5):341-3
18007110
J Am Geriatr Soc. 2000 Mar;48(3):300-4
10733057
J Nutr Health Aging. 2010 Aug;14(7):531-6
20818467
J Nutr Health Aging. 2009 Mar;13(3):242-8
19262961
Prim Care. 2005 Sep;32(3):671-82, vi
16140122
J Nutr Health Aging. 2010 Aug;14(7):563-8
20818472
J Gen Intern Med. 2007 Nov;22(11):1487-92
17823840